← Leaderboards
Zheng Fu
Mayo Clinic
$2,039,776
Attributed
$2,039,776
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $348.8K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,039,776 · 3
By mechanism
R01$1,733,754 · 1
R03$155,250 · 1
F32$150,772 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorigenesisTumorMitoticPropertyRegulationTransgenesMouse ModelPhosphotransferasesOncogenicDown-RegulationPlk1 GeneBiological ModelsProto-OncogenesLinkMitosisCancer EtiologyGeneticAnimal ModelMolecularCancer TypeBaseCessation Of LifeIn Vivo
Grant awards (9)
Define the oncogenic role of Plk1 during hepatocellular carcinoma development using a genetically modified mouse model$155,250
R03 · FY2023 · CA · contact PI
The role of PLK1 in prostate cancer$348,844
R01 · FY2020 · CA · contact PI
The role of PLK1 in prostate cancer$338,378
R01 · FY2019 · CA · contact PI
The role of PLK1 in prostate cancer$348,844
R01 · FY2018 · CA · contact PI
The role of PLK1 in prostate cancer$348,844
R01 · FY2017 · CA · contact PI
The role of PLK1 in prostate cancer$348,844
R01 · FY2016 · CA · contact PI
The Role of Chfr In Tumorigenesis$52,048
F32 · FY2007 · CA · contact PI
The Role of Chfr In Tumorigenesis$50,428
F32 · FY2006 · CA · contact PI
The Role of Chfr In Tumorigenesis$48,296
F32 · FY2005 · CA